021-51111890
购物车（）
sales@molnova.cn
GSK-461364
CAS No. 929095-18-1
GSK-461364 ( GSK-461364A )
产品货号. M16654 CAS No. 929095-18-1
A potent, selective, and reversible ATP-competitive PLK1 inhibitor with Ki of 2.2 nM.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥356 | 有现货 |
|
| 5MG | ￥551 | 有现货 |
|
| 10MG | ￥1021 | 有现货 |
|
| 25MG | ￥1758 | 有现货 |
|
| 50MG | ￥3183 | 有现货 |
|
| 100MG | ￥4755 | 有现货 |
|
| 200MG | ￥6796 | 有现货 |
|
| 500MG | ￥10368 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称GSK-461364
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述A potent, selective, and reversible ATP-competitive PLK1 inhibitor with Ki of 2.2 nM.
-
产品描述A potent, selective, and reversible ATP-competitive PLK1 inhibitor with Ki of 2.2 nM; >390-fold greater selectivity for Plk1 than for Plk2 and Plk3 and 1,000-fold greater selectivity than for a panel of 48 other kinases; shows antiproliferative activity against >120 tumor cell lines and potently inhibits the proliferation with IC50s of <100 nM; shows clear antitumor activity in human tumor xenograft models.Blood Cancer Phase 1 Clinical
-
同义词GSK-461364A
-
通路Cell Cycle/DNA Damage
-
靶点PLK
-
受体PLK1
-
研究领域Cancer
-
适应症Blood cancer
化学信息
-
CAS Number929095-18-1
-
分子量543.60
-
分子式C27H28F3N5O2S
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESO=C(C1=C(O[C@@H](C2=CC=CC=C2C(F)(F)F)C)C=C(N3C=NC4=CC=C(CN5CCN(C)CC5)C=C34)S1)N
-
化学全称2-Thiophenecarboxamide, 5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Olmos D, et al. Clin Cancer Res. 2011 May 15;17(10):3420-30.
2. Gilmartin AG, et al. Cancer Res. 2009 Sep 1;69(17):6969-77.
3. Degenhardt Y, et al. Mol Cancer Ther. 2010 Jul;9(7):2079-89.
2. Gilmartin AG, et al. Cancer Res. 2009 Sep 1;69(17):6969-77.
3. Degenhardt Y, et al. Mol Cancer Ther. 2010 Jul;9(7):2079-89.
产品手册
关联产品
-
Rigosertib sodium
Rigosertib sodium (ON 01910.Na) is a potent, non-ATP-competitive PLK1 inhibitor (IC50=9-10 nM).
-
CFI-400437 dihydroch...
CFI-400437 is a selective and potent polo-like kinase 4 (PLK4) inhibitor.
-
BI-2536
A potent and selective inhibitor of PLK1 with IC50 of 0.83 nM.
